Despite a general downturn in the big pharma sector, Eli Lilly has attracted interest from growth investors due to its successful GLP-1 drug, Mounjaro. This drug has demonstrated significant effectiveness in weight loss, contributing to a remarkable 63% stock price increase in 2024. As analysts speculate on the potential for continued growth, they highlight the company's enhanced earnings expectations, implying that further increases in stock value could be on the horizon, captivating investor interest in a traditionally underperforming sector.
Eli Lilly and its Mounjaro weight-loss drug have seen incredible growth over the course of the past year, surging LLY stock by 63% in 2024.
Analysts are optimistic about Eli Lilly's potential for continued growth, driven by the success of GLP-1 drugs and rising earnings expectations.
Collection
[
|
...
]